1
|
Tuerxun K, Tang RH, Abudoumijiti A, Yusupu Z, Aikebaier A, Mijiti S, Ibrahim I, Cao YL, Yasheng A, Wu YQ. Comparative proteomics analysis of samples from hepatic cystic echinococcosis patients using data-independent acquisition approach. J Proteomics 2024; 301:105191. [PMID: 38697285 DOI: 10.1016/j.jprot.2024.105191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 04/22/2024] [Accepted: 04/29/2024] [Indexed: 05/04/2024]
Abstract
Cystic echinococcosis is a zoonotic disease resulting from infection caused by the larval stage of Echinococcus granulosus. This study aimed to assess the specific proteins that are potential candidates for the development of a vaccine against E. granulosus. The data-independent acquisition approach was employed to identify differentially expressed proteins (DEPs) in E. granulosus samples. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was employed to identify several noteworthy proteins. Results: The DEPs in E. granulosus samples were identified (245 pericystic wall vs. parasite-free yellowish granuloma (PYG, 1725 PY vs. PYG, 2274 PN vs. PYG). Further examination of these distinct proteins revealed their predominant enrichment in metabolic pathways, amyotrophic lateral sclerosis, and neurodegeneration-associated pathways. Notably, among these DEPs, SH3BGRL, MST1, TAGLN2, FABP5, UBE2V2, and RARRES2 exhibited significantly higher expression levels in the PYG group compared with the PY group (P < 0.05). The findings may contribute to the understanding of the pathological mechanisms underlying echinococcosis, providing valuable insights into the development of more effective diagnostic tools, treatment modalities, and preventive strategies. SIGNIFICANCE: CE is a major public health hazard in the western regions of China, Central Asia, South America, the Mediterranean countries, and eastern Africa. Echinococcus granulosus is responsible for zoonotic disease through infection Our analysis focuses on the proteins in various samples by data-dependent acquisition (DIA) for proteomic analysis. The importance of this research is to develop new strategies and targets to protect against E. granulosus infections in humans.
Collapse
Affiliation(s)
- Kahaer Tuerxun
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Rong-Hua Tang
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Aabudouxikuer Abudoumijiti
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Zainuer Yusupu
- Department of Ultrasound, The First People's Hospital of Kashgar, Kashgar Prefecture 844000, China
| | - Aizemaiti Aikebaier
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Salamu Mijiti
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Irshat Ibrahim
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Yan-Long Cao
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Abudoukeyimu Yasheng
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China
| | - Yuan-Quan Wu
- Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Kashgar, 120 Yingbin Road, Kashgar Prefecture 844000, China.
| |
Collapse
|
2
|
Yan M, Liu H, Su Y, Bi X, Yang N, Lin R, Lü G. Inhibition of AMPK activation in Echinococcus granulosus sensu stricto limits the parasite's glucose metabolism and survival. Antimicrob Agents Chemother 2024; 68:e0120223. [PMID: 38349157 PMCID: PMC10916388 DOI: 10.1128/aac.01202-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 01/04/2024] [Indexed: 03/07/2024] Open
Abstract
Cystic echinococcosis (CE) is a zoonotic parasitic disease caused by larvae of the Echinococcus granulosus sensu lato (s.l.) cluster. There is an urgent need to develop new drug targets and drug molecules to treat CE. Adenosine monophosphate (AMP)-activated protein kinase (AMPK), a serine/threonine protein kinase consisting of α, β, and γ subunits, plays a key role in the regulation of energy metabolism. However, the role of AMPK in regulating glucose metabolism in E. granulosus s.l. and its effects on parasite viability is unknown. In this study, we found that targeted knockdown of EgAMPKα or a small-molecule AMPK inhibitor inhibited the viability of E. granulosus sensu stricto (s.s.) and disrupted the ultrastructure. The results of in vivo experiments showed that the AMPK inhibitor had a significant therapeutic effect on E. granulosus s.s.-infected mice and resulted in the loss of cellular structures of the germinal layer. In addition, the inhibition of the EgAMPK/EgGLUT1 pathway limited glucose uptake and glucose metabolism functions in E. granulosus s.s.. Overall, our results suggest that EgAMPK can be a potential drug target for CE and that inhibition of EgAMPK activation is an effective strategy for the treatment of disease.
Collapse
Affiliation(s)
- Mingzhi Yan
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Hui Liu
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Yansen Su
- Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China
- Anhui University, Hefei, China
| | - Xiaojuan Bi
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Ning Yang
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Renyong Lin
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
- Basic Medical College, Xinjiang Medical University, Urumqi, China
| | - Guodong Lü
- State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
- College of Pharmacy, Xinjiang Medical University, Urumqi, China
| |
Collapse
|
3
|
Chen B, Yan M, Gao H, Ma Q, Li L, Lü G, Gong Y, Wen L, Xu S, Wang J, Zhao J. In vitro and in vivo Efficacies of Novel Harmine Derivatives in the Treatment of Cystic Echinococcosis. Drug Des Devel Ther 2023; 17:2441-2454. [PMID: 37637266 PMCID: PMC10454840 DOI: 10.2147/dddt.s419002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 08/08/2023] [Indexed: 08/29/2023] Open
Abstract
Introduction Cystic echinococcosis (CE) is a chronic zoonotic parasitic disease caused by the larvae of the Echinococcus granulosus sensu lato (s.l.) cluster. The current existing drugs have limited therapeutic efficacy against cystic echinococcosis, and thus, there is an urgent need to develop new drugs. Methods In this study, 7 harmine (HM) derivatives were screened and the effects of HM derivatives on E. granulosus sensu stricto (s.s.) were evaluated by in vitro and mouse experiments. The safety of the HM derivatives was assessed by cytotoxicity assays, acute toxicity study in animals and subacute toxicity study. Results These results show that the HM derivatives H-2-168 and DH-004 exhibited more significant antiparasitic effects at an initial concentration of 40 μM. The results of further studies showed that H-2-168 and DH-004 had dose-dependent effects against protoscoleces and had satisfactory therapeutic outcomes in vivo. Electron microscopy observations demonstrated that H-2-168 and DH-004 caused severe disruption of the parasite ultrastructure. Notably, the results of the acute toxicity and subchronic toxicity studies showed that H-2-168 and DH-004 had significantly improved safety. In addition, we found that H-2-168 and DH-004 induced DNA damage in E. granulosus s.s., which may be the mechanism by which these drugs produce their therapeutic effects. Discussion Overall, the data from this work demonstrate that H-2-168 and DH-004 are highly effective candidate compounds with low toxicity for the treatment of CE and will provide a new therapeutic strategy for CE pharmacological treatment.
Collapse
Affiliation(s)
- Bei Chen
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Mingzhi Yan
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Huijing Gao
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Qin Ma
- HuaShiDan Pharmaceutical Company Limited, Urumqi, Xinjiang, People’s Republic of China
| | - Lihua Li
- Xinjiang Urumqi Maternal and Child Health Hospital, Urumqi, Xinjiang, People’s Republic of China
| | - Guodong Lü
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Yuehong Gong
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Limei Wen
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Shaoquan Xu
- College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Jianhua Wang
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| | - Jun Zhao
- First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China
| |
Collapse
|
4
|
Zhou Z, Zhou P, Mu Y, Wang L, Cao Z, Dong S, Bao H, Yang B, Xin M, Li R, Ge RL, Tang F. Therapeutic effect on Alveolar echinococcosis by targeting EM-Leucine aminopeptidase. Front Immunol 2022; 13:1027500. [PMID: 36311709 PMCID: PMC9614657 DOI: 10.3389/fimmu.2022.1027500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 09/30/2022] [Indexed: 11/16/2022] Open
Abstract
Alveolar echinococcosis (AE) is a parasitic disease caused by E. multilocularis metacestodes and it is highly prevalent in the northern hemisphere. We have previously found that vaccination with E. multilocularis Leucine aminopeptidase (EM-LAP) induced specific immune response and had an inhibiting effect on the parasites. In this study, the therapeutic effect of recombinant EM-LAP (rEM-LAP) on AE was evaluated and verified using Ubenimex, a broad-spectrum inhibitor of LAP. The results reveal that rEM-LAP could inhibit cyst growth and invasion and induce specific immunity response in BALB/c mice infected with E. multilocularis protoscoleces. The ultrasonic, MRI, and morphological results show that treatment with rEM-LAP inhibits E. multilocularis infection and reduces cyst weight, number, fibrosis and invasion. The same effect is observed for the treatment with Ubenimex by inhibiting LAP activity. The indirect ELISA shows that rEM-LAP could induce specific immunity response and produce high levels of IgG, IgG1, IgG2a, IgM, and IgA, and the serum levels of IFN-γ and IL-4 are significantly increased compared to the control groups, indicating that treatment with rEM-LAP leads to a Th1 and Th2 mixed-type immune response. This study suggests that EM-LAP could be a potential therapeutic target of E. multilocularis infection.
Collapse
Affiliation(s)
- Zhen Zhou
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
| | - Pei Zhou
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
| | - Yalin Mu
- Department of Medical Imaging Center, Qinghai University Affiliated Hospital, Xining, China
| | - Lei Wang
- Department of Pathology, The Second Xiangya Hospital DE Central South University, Changsha, China
| | - Zhenjin Cao
- Department of Medical Imaging Center, Qinghai University Affiliated Hospital, Xining, China
| | - Shizhong Dong
- Department of Medical Imaging Center, Qinghai University Affiliated Hospital, Xining, China
| | - Haihua Bao
- Department of Medical Imaging Center, Qinghai University Affiliated Hospital, Xining, China
| | - Baoliang Yang
- Department of ENT, Qinghai Red Cross Hospital, Xining, China
| | - Minyuan Xin
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
| | - Runle Li
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
- *Correspondence: Runle Li, ; Ri-Li Ge, ; Feng Tang,
| | - Ri-Li Ge
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
- *Correspondence: Runle Li, ; Ri-Li Ge, ; Feng Tang,
| | - Feng Tang
- Research Center for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai-Utah Joint Research Key Lab for High Altitude Medicine, Qinghai University, Xining, China
- Qinghai Provincial Key Laboratory of Plateau Medical Application, Key Laboratory of Ministry of Education, Qinghai University, Xining, China
- *Correspondence: Runle Li, ; Ri-Li Ge, ; Feng Tang,
| |
Collapse
|